Betoxycaine

Betoxycaine

SCHEMBL25758

CCCCOc1ccc(C(=O)OCCOCCN(CC)CC)cc1N

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.77
SCN1A P35498 5/20 0.77
SCN2A Q99250 5/20 0.77
SCN3A Q9NY46 5/20 0.77
CYP1A2 P05177 5/20 0.77
HRH3 Q9Y5N1 3/20 0.77
KCNH2 Q12809 3/20 0.77
CYP3A4 P08684 3/20 0.77
MAOA P21397 2/20 0.77
CYP2C19 P33261 2/20 0.77
SIGMAR1 Q99720 1/20 0.77
TSHR P16473 4/20 0.72
SLC6A3 Q01959 2/20 0.72
SLC6A2 P23975 1/20 0.72
HIF1A Q16665 1/20 0.72
RAD52 P43351 1/20 0.71
HTR3A P46098 1/20 0.52
BLM P54132 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 4/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Betoxycaine SCHEMBL6898673 0.95 CYP2D6 (0.82) CYP2D6SCN1ASCN2ASCN3ACYP1A2
SCHEMBL3260333 0.90 CYP1A2 (0.61) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Proparacaine SCHEMBL29805494 0.87 CYP2D6 (1.00) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Proparacaine SCHEMBL23334 0.87 CYP2D6 (1.00) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Proparacaine SCHEMBL30675347 0.86 CYP2D6 (0.98) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Proparacaine SCHEMBL9872795 0.86 CYP2D6 (0.98) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Proparacaine SCHEMBL23333 0.86 CYP2D6 (0.98) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Proparacaine SCHEMBL93880 0.86 CYP2D6 (0.98) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Benoxinate SCHEMBL25087 0.84 CYP2D6 (1.00) CYP2D6SCN1ASCN2ASCN3ACYP1A2
Benoxinate SCHEMBL30849863 0.84 CYP2D6 (1.00) CYP2D6SCN1ASCN2ASCN3ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1799 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT UNIV KOREA RES & BUS FOUND (KR) 2026-04-30 US claimed
WO-2025235864-A1 COATED NEEDLE ADMINISTRATION SYSTEMS EVOLUS, INC. (US) 2025-11-13 WO claimed
EP-4578441-A1 TREATMENT OF LOCALIZED PAIN PlantTec Medical GmbH (DE) 2025-07-02 EP claimed
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics BIOPOLIMERI S.R.L. (IT) 2025-06-17 US claimed
US-20250186364-A1 COMBINATION OF ANTISPASMODIC AND ANESTHETIC AGENTS FOR TOPICAL PRODUCTS AND THEIR METHOD OF USE PRIMA INNOVATIONS, LLC 2025-06-12 US claimed
EP-4362994-B1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS BIOPOLIMERI S R L (IT) 2025-03-12 EP claimed
EP-3703802-B9 NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF CLEXIO BIOSCIENCES LTD (IL) 2024-12-04 EP claimed
EP-3703802-B1 NASAL DELIVERY DEVICES AND METHODS OF USE THEREOF CLEXIO BIOSCIENCES LTD (IL) 2024-10-16 EP claimed
US-20240293311-A1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS BIOPOLIMERI S.R.L. (IT) 2024-09-05 US claimed
US-20240261464-A1 POWDER FORMULATION FOR TISSUE REPAIR, PREPARATION METHOD THEREFOR, AND INJECTABLE COMPOSITION FOR TISSUE REPAIR, COMPRISING SAME SAMYANG HOLDINGS CORPORATION (KR) 2024-08-08 US claimed
US-20010055607-A1 COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES BHL PATENT HOLDINGS LLC 2001-12-27 US claimed
WO-2001080797-A1 MEDICATED WRAP HYSON MORTON I (US) 2001-11-01 WO claimed
EP-1027015-A4 CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE GALIN MILES A (US) 2001-06-27 EP claimed
WO-2001043733-A2 COMPOSITIONS, KITS, APPARATUS, AND METHODS FOR INHIBITING CEPHALIC INFLAMMATION LEVIN BRUCE H (US) 2001-06-21 WO claimed
US-20010004644-A1 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation LEVIN BRUCE H (US) 2001-06-21 US claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-1027015-A1 CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE Galin, Miles A. (US) 2000-08-16 EP claimed
US-5972326-A Controlled release of pharmaceuticals in the anterior chamber of the eye IOLTECH (FR) 1999-10-26 US claimed
WO-1998041171-A1 CONTROLLED RELEASE OF PHARMACEUTICALS IN THE ANTERIOR CHAMBER OF THE EYE GALIN MILES A (US) 1998-09-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010055607-A1 COMPOSITIONS, KITS, AND METHODS FOR INHIBITING CEREBRAL NEUROVASCULAR DISORDERS AND MUSCULAR HEADACHES TNNC1, KIT, PDE3A CYP2D6 2876/4885SCN1A 43/4885SCN2A 137/4885
US-12329856-B2 Crosslinked hyaluronic acid composition with local anesthetics CD44, HCAR3, HCAR2 CYP2D6 1977/4885SCN1A 2618/4885SCN2A 2486/4885
US-20010004644-A1 Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation CXCR5, CCL5, C5AR2 CYP2D6 2490/4885SCN1A 2794/4885SCN2A 3499/4885
US-20260115156-A1 INJECTABLE COMPOSITION INCLUDING HYDROGEL CONTAINING ANESTHETIC AGENT CES2, DAGLA, ACHE CYP2D6 71/4885SCN1A 1562/4885SCN2A 501/4885
US-20240293311-A1 CROSSLINKED HYALURONIC ACID COMPOSITION WITH LOCAL ANESTHETICS CD44, HCAR3, HCAR2 CYP2D6 1977/4885SCN1A 2618/4885SCN2A 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.